JP2010508363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010508363A5 JP2010508363A5 JP2009535437A JP2009535437A JP2010508363A5 JP 2010508363 A5 JP2010508363 A5 JP 2010508363A5 JP 2009535437 A JP2009535437 A JP 2009535437A JP 2009535437 A JP2009535437 A JP 2009535437A JP 2010508363 A5 JP2010508363 A5 JP 2010508363A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- membered
- heterocyclyl
- heteroaryl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001931 aliphatic group Chemical group 0.000 claims description 66
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 239000001257 hydrogen Substances 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 125000002723 alicyclic group Chemical group 0.000 claims description 28
- 150000002431 hydrogen Chemical group 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical group 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 102000042838 JAK family Human genes 0.000 claims description 6
- 108091082332 JAK family Proteins 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 201000001881 impotence Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 206010003225 Arteriospasm coronary Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 4
- 208000006029 Cardiomegaly Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 208000001286 intracranial vasospasm Diseases 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 230000010410 reperfusion Effects 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 239000011593 sulfur Chemical group 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- -1 1,2-methylenedioxy Chemical group 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 claims description 2
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010059109 Cerebral vasoconstriction Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 2
- 241000239366 Euphausiacea Species 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 206010019842 Hepatomegaly Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010020880 Hypertrophy Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000003782 Raynaud disease Diseases 0.000 claims description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 2
- 101710112791 Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 2
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims description 2
- 101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 claims description 2
- 206010047163 Vasospasm Diseases 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 231100000360 alopecia Toxicity 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000008694 endothelial dysfunction Effects 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 125000006161 haloaliphatic group Chemical group 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 230000014511 neuron projection development Effects 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 206010036600 Premature labour Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000026440 premature labor Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- KZEDBHGMDQYYNT-UHFFFAOYSA-N C(C(c1c[nH]2)Nc(cccc3)c3-c3c1c2ncn3)OCc1ccccc1 Chemical compound C(C(c1c[nH]2)Nc(cccc3)c3-c3c1c2ncn3)OCc1ccccc1 KZEDBHGMDQYYNT-UHFFFAOYSA-N 0.000 description 1
- LXEVBBVJFDSXQF-UHFFFAOYSA-N C(C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3)c1ccccc1 Chemical compound C(C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3)c1ccccc1 LXEVBBVJFDSXQF-UHFFFAOYSA-N 0.000 description 1
- XXABPNQNJUEFOF-UHFFFAOYSA-N C1Oc2cc(C(c3c[nH]4)Nc5ccccc5-c5c3c4ncc5)ccc2O1 Chemical compound C1Oc2cc(C(c3c[nH]4)Nc5ccccc5-c5c3c4ncc5)ccc2O1 XXABPNQNJUEFOF-UHFFFAOYSA-N 0.000 description 1
- 208000014997 Crohn colitis Diseases 0.000 description 1
- PMZGUHFIOUYAPZ-UHFFFAOYSA-N FC(c1c(C2Nc3ccccc3-c3ccnc4c3c2c[nH]4)c(F)ccc1)(F)F Chemical compound FC(c1c(C2Nc3ccccc3-c3ccnc4c3c2c[nH]4)c(F)ccc1)(F)F PMZGUHFIOUYAPZ-UHFFFAOYSA-N 0.000 description 1
- ZGTRBSABWYYFNJ-UHFFFAOYSA-N Fc(c(C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3)c1F)ccc1F Chemical compound Fc(c(C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3)c1F)ccc1F ZGTRBSABWYYFNJ-UHFFFAOYSA-N 0.000 description 1
- RUDQSTSEVNDVSX-UHFFFAOYSA-N Fc(cc(C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3)cc1)c1Cl Chemical compound Fc(cc(C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3)cc1)c1Cl RUDQSTSEVNDVSX-UHFFFAOYSA-N 0.000 description 1
- JWPFBCRJPHMGGQ-UHFFFAOYSA-N Fc(cc1)cc(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)c1F Chemical compound Fc(cc1)cc(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)c1F JWPFBCRJPHMGGQ-UHFFFAOYSA-N 0.000 description 1
- FSWKNYIWQCOMFX-UHFFFAOYSA-N Fc(cc1F)c(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)cc1F Chemical compound Fc(cc1F)c(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)cc1F FSWKNYIWQCOMFX-UHFFFAOYSA-N 0.000 description 1
- NZPFOGAFXJOEPL-UHFFFAOYSA-N Fc(ccc(C1Nc2ccccc2-c2ccnc3c2c1c[nH]3)c1F)c1F Chemical compound Fc(ccc(C1Nc2ccccc2-c2ccnc3c2c1c[nH]3)c1F)c1F NZPFOGAFXJOEPL-UHFFFAOYSA-N 0.000 description 1
- DQKOEJAKTBEUII-UHFFFAOYSA-N Fc1c(C(c2c[nH]3)Nc(cccc4)c4-c4c2c3ncc4)cccn1 Chemical compound Fc1c(C(c2c[nH]3)Nc(cccc4)c4-c4c2c3ncc4)cccn1 DQKOEJAKTBEUII-UHFFFAOYSA-N 0.000 description 1
- PRZXJAIFSLWDCR-UHFFFAOYSA-N Fc1cc(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)cc(F)c1 Chemical compound Fc1cc(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)cc(F)c1 PRZXJAIFSLWDCR-UHFFFAOYSA-N 0.000 description 1
- ADQWZEJYOPEHOF-UHFFFAOYSA-N Fc1cc(Cl)c(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)cc1 Chemical compound Fc1cc(Cl)c(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)cc1 ADQWZEJYOPEHOF-UHFFFAOYSA-N 0.000 description 1
- UBHBMONOIRNUJF-UHFFFAOYSA-N Fc1cc(F)c(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)cc1 Chemical compound Fc1cc(F)c(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)cc1 UBHBMONOIRNUJF-UHFFFAOYSA-N 0.000 description 1
- OSJBWAPYRGIWII-UHFFFAOYSA-N Fc1cccc(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)c1F Chemical compound Fc1cccc(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)c1F OSJBWAPYRGIWII-UHFFFAOYSA-N 0.000 description 1
- XFZIBBJICPJLMJ-UHFFFAOYSA-N Fc1cccc(Cl)c1C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3 Chemical compound Fc1cccc(Cl)c1C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3 XFZIBBJICPJLMJ-UHFFFAOYSA-N 0.000 description 1
- SQENUGNVGCTABM-UHFFFAOYSA-N OC(C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3)=O Chemical compound OC(C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3)=O SQENUGNVGCTABM-UHFFFAOYSA-N 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- SOVRHBFGUWDKKW-UHFFFAOYSA-N [O-][N+](c1c(C2Nc3ccccc3-c3ccnc4c3c2c[nH]4)cccc1)=O Chemical compound [O-][N+](c1c(C2Nc3ccccc3-c3ccnc4c3c2c[nH]4)cccc1)=O SOVRHBFGUWDKKW-UHFFFAOYSA-N 0.000 description 1
- CUOFXLXWOAEHGY-UHFFFAOYSA-N c([nH]c1ncc2)c3c1c2-c1ccccc1NC3c1cnccc1 Chemical compound c([nH]c1ncc2)c3c1c2-c1ccccc1NC3c1cnccc1 CUOFXLXWOAEHGY-UHFFFAOYSA-N 0.000 description 1
- UPJZSWHGAMYVKL-UHFFFAOYSA-N c([nH]c1ncc2)c3c1c2-c1ccccc1NC3c1ncccc1 Chemical compound c([nH]c1ncc2)c3c1c2-c1ccccc1NC3c1ncccc1 UPJZSWHGAMYVKL-UHFFFAOYSA-N 0.000 description 1
- NGSGFCQHFWSVGJ-UHFFFAOYSA-N c1c(C(c2ccccc2)Nc2ccccc2-2)c3c-2ncnc3[nH]1 Chemical compound c1c(C(c2ccccc2)Nc2ccccc2-2)c3c-2ncnc3[nH]1 NGSGFCQHFWSVGJ-UHFFFAOYSA-N 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000037805 labour Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85586206P | 2006-11-01 | 2006-11-01 | |
| PCT/US2007/083134 WO2008079521A2 (en) | 2006-11-01 | 2007-10-31 | Tricyclic heteroaryl compounds useful as inhibitors of janus kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010508363A JP2010508363A (ja) | 2010-03-18 |
| JP2010508363A5 true JP2010508363A5 (https=) | 2011-12-15 |
Family
ID=39561862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535437A Pending JP2010508363A (ja) | 2006-11-01 | 2007-10-31 | ヤヌスキナーゼの阻害剤として有用な三環系ヘテロアリール化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8163732B2 (https=) |
| EP (1) | EP2079740B1 (https=) |
| JP (1) | JP2010508363A (https=) |
| KR (1) | KR20090082453A (https=) |
| CN (1) | CN101568540A (https=) |
| AU (1) | AU2007338574A1 (https=) |
| CA (1) | CA2668159A1 (https=) |
| IL (1) | IL198510A0 (https=) |
| MX (1) | MX2009004771A (https=) |
| NO (1) | NO20092130L (https=) |
| RU (1) | RU2009120622A (https=) |
| WO (1) | WO2008079521A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2540964T3 (es) * | 2009-06-08 | 2015-07-15 | Takeda Pharmaceutical Company Limited | Compuestos de dihidropirrolonaftiridinona como inhibidores de JAK |
| KR101438293B1 (ko) * | 2009-09-21 | 2014-09-05 | 에프. 호프만-라 로슈 아게 | Ｊａｋ의 매크로사이클릭 억제자 |
| WO2012078802A1 (en) * | 2010-12-08 | 2012-06-14 | Takeda Pharmaceutical Company Limited | PREPARATION OF SUBSTITUTED-4,5-DIHYDROPYRROLO[4,3,2-de][2,6]NAPHTHYRIDIN-3(1H)-ONES |
| WO2012085176A1 (en) * | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
| US10821111B2 (en) | 2011-11-30 | 2020-11-03 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
| ES3018133T3 (en) | 2011-11-30 | 2025-05-14 | Univ Emory | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| UY35395A (es) * | 2013-03-12 | 2014-10-31 | Abbvie Inc | Inhibidores de bromodominios tetracíclicos |
| CN105636962B (zh) * | 2013-10-15 | 2017-10-13 | 靳博涵 | 新型化合物、用途及其制备方法 |
| US9328112B2 (en) | 2014-02-06 | 2016-05-03 | Abbvie Inc. | Tetracyclic CDK9 kinase inhibitors |
| TW201613919A (en) | 2014-07-02 | 2016-04-16 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| CN110914265B (zh) * | 2017-05-15 | 2022-12-23 | 密歇根大学董事会 | 作为lsd-1抑制剂的吡咯并[2,3-c]吡啶和相关类似物 |
| EP3947737A2 (en) | 2019-04-02 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| EP3955920A1 (en) | 2019-04-16 | 2022-02-23 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| ES2253930T3 (es) * | 1998-09-18 | 2006-06-01 | ABBOTT GMBH & CO. KG | 4-aminopirrolopirimidinas como inhibidores de quinasa. |
| CA2450769A1 (en) * | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| JP2005528443A (ja) * | 2002-05-30 | 2005-09-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｊａｋキナーゼおよびｃｄｋ２プロテインキナーゼのインヒビター |
| ES2364340T3 (es) * | 2004-03-30 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | Azaindoles útiles como inhibidores de jak y otras proteína quinasas. |
| WO2006015123A1 (en) * | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| WO2006050076A1 (en) * | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| KR20070104641A (ko) | 2005-02-03 | 2007-10-26 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제의 억제제로 유용한 피롤로피리미딘 |
| RU2387653C2 (ru) * | 2005-05-16 | 2010-04-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназ |
-
2007
- 2007-10-31 RU RU2009120622/04A patent/RU2009120622A/ru not_active Application Discontinuation
- 2007-10-31 AU AU2007338574A patent/AU2007338574A1/en not_active Abandoned
- 2007-10-31 CA CA002668159A patent/CA2668159A1/en not_active Abandoned
- 2007-10-31 MX MX2009004771A patent/MX2009004771A/es active IP Right Grant
- 2007-10-31 KR KR1020097011345A patent/KR20090082453A/ko not_active Withdrawn
- 2007-10-31 JP JP2009535437A patent/JP2010508363A/ja active Pending
- 2007-10-31 CN CNA2007800480929A patent/CN101568540A/zh active Pending
- 2007-10-31 EP EP07872337A patent/EP2079740B1/en not_active Not-in-force
- 2007-10-31 WO PCT/US2007/083134 patent/WO2008079521A2/en not_active Ceased
-
2009
- 2009-05-01 US US12/434,154 patent/US8163732B2/en not_active Expired - Fee Related
- 2009-05-03 IL IL198510A patent/IL198510A0/en unknown
- 2009-06-02 NO NO20092130A patent/NO20092130L/no not_active Application Discontinuation
-
2012
- 2012-03-26 US US13/429,826 patent/US20130090331A1/en not_active Abandoned
-
2014
- 2014-01-27 US US14/164,419 patent/US20140206671A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010508363A5 (https=) | ||
| RU2009120622A (ru) | Трициклические гетероарильные соединения в качестве ингибиторов янус-киназы | |
| JP2010520264A5 (https=) | ||
| KR102547188B1 (ko) | 테트라하이드로피라닐 아미노-피롤로피리미디논 및 이의 사용 방법 | |
| KR100968175B1 (ko) | 신규한 트리시클릭 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
| JP2020520924A5 (https=) | ||
| RU2006138621A (ru) | Азаиндолы, полезные в качестве ингибиторов rock и других протеинкиназ | |
| JP5579724B2 (ja) | ホスファチジルイノシトール−３−キナーゼ（ｐｉ−３キナーゼ）阻害剤としてのテトラ−アザ−複素環 | |
| JP2010540562A5 (https=) | ||
| JP2016500112A (ja) | ラパマイシン類似体及びその製作方法 | |
| JP2010522210A5 (https=) | ||
| JP2010513386A5 (https=) | ||
| KR20090106633A (ko) | ＰＤＥ5 억제제로서 유용한 6-벤질-2,3,4,7-테트라히드로-인돌로[2,3-ｃ]퀴놀린 화합물 | |
| JP2006517976A5 (https=) | ||
| MXPA05011103A (es) | Compuestos de quinazolina. | |
| CN112409294A (zh) | 苯并噻嗪酮衍生物及其制备方法与作为抗结核药物的应用 | |
| TW201040148A (en) | Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof | |
| JPH05112572A (ja) | １−（ピリド〔３，４−ｂ〕−１，４−オキサジニル−４−イル）−１Ｈ−インドール類 | |
| DE69106902T2 (de) | Imidazopyridazine, ihre Herstellung und Verwendung. | |
| US9956208B2 (en) | Compounds for the treatment of cancer and inflammatory diseases | |
| JPWO2015170693A1 (ja) | シクロヘキシルピリジン誘導体 | |
| DE602005000676T2 (de) | Triazacyclopenta[cd]indenderivate | |
| JP6464244B2 (ja) | Ｔｅｒｔ−ブチル ｎ−［２−｛４−［６−アミノ−５−（２，４−ジフルオロベンゾイル）−２−オキソピリジン−１（２ｈ）−イル］−３，５−ジフルオロフェニル｝エチル）−ｌ−アラニネート又はその製薬上許容され得る塩、水和物もしくは溶媒和物 | |
| DE68910593T2 (de) | Chinolinoncarbonsäuren. | |
| GB2388111A (en) | Novel imidazotriazinone compounds |